AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and resp… Read more
AstraZeneca Pharma India Limited (ASTRAZEN) - Net Assets
Latest net assets as of September 2025: ₹7.99 Billion INR
Based on the latest financial reports, AstraZeneca Pharma India Limited (ASTRAZEN) has net assets worth ₹7.99 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹16.15 Billion) and total liabilities (₹8.16 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹7.99 Billion |
| % of Total Assets | 49.49% |
| Annual Growth Rate | 11.0% |
| 5-Year Change | 68.87% |
| 10-Year Change | 287.07% |
| Growth Volatility | 23.26 |
AstraZeneca Pharma India Limited - Net Assets Trend (2005–2025)
This chart illustrates how AstraZeneca Pharma India Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AstraZeneca Pharma India Limited (2005–2025)
The table below shows the annual net assets of AstraZeneca Pharma India Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹7.70 Billion | +8.21% |
| 2024-03-31 | ₹7.12 Billion | +20.94% |
| 2023-03-31 | ₹5.89 Billion | +15.11% |
| 2022-03-31 | ₹5.11 Billion | +12.11% |
| 2021-03-31 | ₹4.56 Billion | +25.17% |
| 2020-03-31 | ₹3.64 Billion | +21.16% |
| 2019-03-31 | ₹3.01 Billion | +21.82% |
| 2018-03-31 | ₹2.47 Billion | +13.17% |
| 2017-03-31 | ₹2.18 Billion | +9.64% |
| 2016-03-31 | ₹1.99 Billion | +32.02% |
| 2015-03-31 | ₹1.51 Billion | -12.14% |
| 2014-03-31 | ₹1.72 Billion | +72.02% |
| 2013-03-31 | ₹997.53 Million | -47.30% |
| 2012-03-31 | ₹1.89 Billion | +5.34% |
| 2011-03-31 | ₹1.80 Billion | +24.34% |
| 2010-03-31 | ₹1.45 Billion | +24.42% |
| 2009-03-31 | ₹1.16 Billion | -26.97% |
| 2008-03-31 | ₹1.59 Billion | +12.23% |
| 2007-03-31 | ₹1.42 Billion | +11.42% |
| 2006-03-31 | ₹1.27 Billion | +33.13% |
| 2005-03-31 | ₹955.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AstraZeneca Pharma India Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 632720000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹6.33 Billion | 82.13% |
| Common Stock | ₹50.00 Million | 0.65% |
| Other Comprehensive Income | ₹795.00 Million | 10.32% |
| Other Components | ₹531.30 Million | 6.90% |
| Total Equity | ₹7.70 Billion | 100.00% |
AstraZeneca Pharma India Limited Competitors by Market Cap
The table below lists competitors of AstraZeneca Pharma India Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Veken Elite
SHG:600152
|
$449.25 Million |
|
Electrolux Professional AB (publ)
OTCGREY:ECTXF
|
$449.33 Million |
|
Armada Hflr Pr
NYSE:AHH
|
$449.55 Million |
|
Internacional de Cerámica S.A.B. de C.V
MX:CERAMICB
|
$449.64 Million |
|
Optics Technology Holding Co Ltd
SHE:300489
|
$448.97 Million |
|
PAR TECHNOLOGY DL-02
F:35U
|
$448.95 Million |
|
Gruppo MutuiOnline S.p.A.
LSE:0O2B
|
$448.92 Million |
|
Djerriwarrh Investments Ltd
AU:DJW
|
$448.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AstraZeneca Pharma India Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,119,200,000 to 7,703,500,000, a change of 584,300,000 (8.2%).
- Net income of 1,157,400,000 contributed positively to equity growth.
- Dividend payments of 600,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 230,800,000.
- Other factors decreased equity by 203,900,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹1.16 Billion | +15.02% |
| Dividends Paid | ₹600.00 Million | -7.79% |
| Other Comprehensive Income | ₹230.80 Million | +3.0% |
| Other Changes | ₹-203.90 Million | -2.65% |
| Total Change | ₹- | 8.21% |
Book Value vs Market Value Analysis
This analysis compares AstraZeneca Pharma India Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 221.10x to 27.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹38.22 | ₹8449.50 | x |
| 2006-03-31 | ₹50.88 | ₹8449.50 | x |
| 2007-03-31 | ₹56.69 | ₹8449.50 | x |
| 2008-03-31 | ₹63.72 | ₹8449.50 | x |
| 2009-03-31 | ₹46.46 | ₹8449.50 | x |
| 2010-03-31 | ₹57.81 | ₹8449.50 | x |
| 2011-03-31 | ₹71.88 | ₹8449.50 | x |
| 2012-03-31 | ₹75.71 | ₹8449.50 | x |
| 2013-03-31 | ₹39.90 | ₹8449.50 | x |
| 2014-03-31 | ₹68.64 | ₹8449.50 | x |
| 2015-03-31 | ₹60.30 | ₹8449.50 | x |
| 2016-03-31 | ₹62.41 | ₹8449.50 | x |
| 2017-03-31 | ₹89.15 | ₹8449.50 | x |
| 2018-03-31 | ₹98.77 | ₹8449.50 | x |
| 2019-03-31 | ₹120.32 | ₹8449.50 | x |
| 2020-03-31 | ₹145.78 | ₹8449.50 | x |
| 2021-03-31 | ₹182.47 | ₹8449.50 | x |
| 2022-03-31 | ₹204.56 | ₹8449.50 | x |
| 2023-03-31 | ₹235.48 | ₹8449.50 | x |
| 2024-03-31 | ₹284.77 | ₹8449.50 | x |
| 2025-03-31 | ₹308.16 | ₹8449.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AstraZeneca Pharma India Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.02%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.74%
- • Asset Turnover: 1.13x
- • Equity Multiplier: 1.97x
- Recent ROE (15.02%) is below the historical average (15.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 26.95% | 13.36% | 1.15x | 1.75x | ₹161.96 Million |
| 2006 | 33.85% | 19.36% | 1.27x | 1.38x | ₹303.39 Million |
| 2007 | 34.39% | 18.43% | 1.10x | 1.69x | ₹345.64 Million |
| 2008 | 38.58% | 20.67% | 1.21x | 1.54x | ₹455.28 Million |
| 2009 | 63.57% | 20.84% | 1.23x | 2.49x | ₹622.20 Million |
| 2010 | 39.87% | 14.95% | 1.65x | 1.62x | ₹431.65 Million |
| 2011 | 35.69% | 10.80% | 1.92x | 1.72x | ₹461.61 Million |
| 2012 | 10.44% | 3.72% | 1.55x | 1.81x | ₹8.37 Million |
| 2013 | -89.75% | -22.94% | 1.27x | 3.07x | ₹-995.08 Million |
| 2014 | -0.30% | -0.11% | 1.14x | 2.42x | ₹-176.68 Million |
| 2015 | -13.82% | -4.44% | 1.14x | 2.73x | ₹-359.15 Million |
| 2016 | 3.37% | 0.93% | 1.26x | 2.88x | ₹-103.42 Million |
| 2017 | 9.00% | 3.69% | 1.31x | 1.86x | ₹-22.37 Million |
| 2018 | 10.49% | 4.54% | 1.24x | 1.87x | ₹12.17 Million |
| 2019 | 18.10% | 7.48% | 1.30x | 1.87x | ₹243.70 Million |
| 2020 | 19.81% | 8.68% | 1.18x | 1.94x | ₹357.66 Million |
| 2021 | 20.45% | 11.54% | 1.04x | 1.70x | ₹476.83 Million |
| 2022 | 12.05% | 7.65% | 0.94x | 1.67x | ₹104.61 Million |
| 2023 | 16.87% | 9.90% | 1.02x | 1.67x | ₹404.21 Million |
| 2024 | 22.69% | 12.47% | 1.20x | 1.51x | ₹903.18 Million |
| 2025 | 15.02% | 6.74% | 1.13x | 1.97x | ₹387.05 Million |
Industry Comparison
This section compares AstraZeneca Pharma India Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AstraZeneca Pharma India Limited (ASTRAZEN) | ₹7.99 Billion | 26.95% | 1.02x | $449.10 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |